Known targets — ChEMBL curated mechanism
ADRB1ADRB2ATP4AATP4BAXLCHRM2CHRM3DRD2FLT3HRH1HTR2AHTR2BHTR2CKCNH2KMT2AMAP2K1MAP2K2MEN1MLNRPLK4RENS1PR1SLC6A2SLC6A4atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.59 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.52 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.52 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL6697653 | 0.85 | DPP4 (0.62) | DPP4DPP8DPP9DPP7 | |
| Fumaric Acid SCHEMBL6703274 | 0.84 | DPP4 (0.64) | DPP4DPP8DPP9DPP7 | |
| Fumaric Acid SCHEMBL6700507 | 0.83 | DPP4 (0.61) | DPP4DPP8DPP9DPP7 | |
| Fumaric Acid SCHEMBL6701204 | 0.82 | DPP4 (0.67) | DPP4DPP7 | |
| Fumaric Acid SCHEMBL6704377 | 0.82 | DPP4 (0.57) | DPP4DPP8DPP9DPP7 | |
| Fumaric Acid SCHEMBL6986745 | 0.82 | DPP4 (0.57) | DPP4DPP8DPP9DPP7 | |
| Fumaric Acid SCHEMBL6705064 | 0.82 | DPP4 (0.57) | DPP4DPP8DPP9DPP7 | |
| Fumaric Acid SCHEMBL6702988 | 0.82 | DPP4 (0.59) | DPP4DPP8DPP9DPP7 | |
| Fumaric Acid SCHEMBL6697122 | 0.82 | DPP4 (0.68) | DPP4DPP8DPP9DPP7 | |
| Fumaric Acid SCHEMBL6702288 | 0.82 | DPP4 (0.72) | DPP4DPP8DPP9DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-09-16 | — | — | US | disclosed |
| EP-1354882-A1 | DIPEPTIDYL PEPTIDASE IV INHIBITOR | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-10-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180925-A1 | Dipeptidylpeptidase-IV inhibitor | DPP4, DPP3, DPP9 | DPP4 1/4885DPP8 6/4885DPP9 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.